BRAF and neoplasm: To be able to correlate BRAF-mutant protein expression with tumor characteristics and morphological tumor heterogeneity, we first determined the correlation between BRAFV600E-mutant immunopositivity assessed with the specific monoclonal antibody VE1 and the presence of the mutation as determined with pyrosequencing in 45 out of 149 randomly selected tumor samples.